COBALT HEALTH

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +9.8%

  £24,524,912 → £26,927,825

• Cash

  +1%

  £3,089,763 → £3,120,283

• Net assets

  -1.5%

  £31,869,382 → £31,399,722

• Employees

  +4.6%

  174 → 182

• Wages

  +4.1%

  £6,490,353 → £6,753,619

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. COBALT HEALTH 2015-01-05 → present
2. COBALT UNIT APPEAL FUND 2002-02-04 → 2015-01-05

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Crowe U.K. LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.”

Group structure

1. COBALT HEALTH · parent
   1. The Cobalt Unit Appeal Fund Limited 1% · England and Wales · dormant

Significant events

• “This year marked by change, but also anchored in the continuous and consistent professionalism and compassion for which we are well known.”
• “Jim Brown was welcomed as our new Chief Executive Officer.”
• “Malcolm MacKeith retired after 10 years of dedication as Finance Director and latterly as Chief Executive.”
• “We delivered over 3,100 days of lung cancer screening, identifying patients who benefitted from treatment at an early, more treatable stage.”
• “Over 1,300 NHS breast cancer research patients were recruited onto a key trial by Cobalt's research nurses.”
• “Our team supporting the Gloucestershire Community Diagnostic Centre delivered 400 scans per week for NHS patients.”
• “We have invested in AI software for our scanners, improving image quality and shortening scanning times for patients.”
• “In 2024/25, we delivered a record number (4,976) PET/CT scans for patients from the three counties.”
• “The targeted lung health check programmes have been renamed lung cancer screening services. We continued to support six services, delivering 3,100 days of screening, up from 2,024 in 2023/24.”
• “A new operations centre was created to improve visibility, response rates, and control costs for lung cancer screening services.”
• “We started providing a cardiac MRI service for patients.”
• “Our first relocatable PET/CT unit was completed in Summer 2024 and commenced service in October.”
• “The trustees approved a plan to upgrade all three 3.0 Tesla MRI scanners, with the first being undertaken in 2024/25.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

0

last 24 months

Officers appointed

2

last 12 months

Officers resigned

2

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.